NOV 02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(MBHB Case No. 02-742-E; 400/130)		
on of:	)	
gen et al.	j	
/664,668	) Examiner: TBA )	
eptember 18, 2003	Group Art Unit: 1635	
promise 20, 2000	) Confirmation No. 5711	
cular Endothelial Growth Factor or Gene Expression Using Short	; r )	
	ion of: gen et al. /664,668 eptember 18, 2003 erference of Mediated Inhibition ular Endothelial Growth Factor scular Endothelial Growth Factor	

Commissioner of Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

## TRANSMITTAL LETTER

In regard to the above identified application:


- 1. We are transmitting herewith the attached papers for the above identified new patent application:
  - Second Supplemental Information Disclosure Statement;
    - Second Supplemental Information Disclosure Statement (IDS) PTO/SB/08B Form;
  - Copies of IDS Citations for S/N 10/664,668 (Total 7 other documents); and
  - $\boxtimes$ Return Receipt Postcard.
- 2. With respect to additional fees, no additional fee is required.
- 3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
- CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this 4. Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 2313-1450 on 10/30 2006.

By:

.isa M.W. Hillman

Registration No. 43,673

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 SOUTH WACKER DRIVE CHICAGO, ILLINOIS 60606 TELEPHONE (312) 913-0001 FACSIMILE: (312) 913-0002



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 02-742-E; 400/130)

In the Application of:

McSwiggen et al.	Examiner: TBA			
Serial No.: 10/664,668	Group Art Unit: 1635			
Filing Date: September 18, 2003	Confirmation No. 5711			
For: RNA Interference of Mediated Inhibition	Of Vascular Endothelial Growth Factor	And Vascular Endothelial Growth Factor	Receptor Gene Expression Using Short	Interfering Nucleic Acid (siNA)

## SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Second Supplemental Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO/SB/08B form.

The Office has amended the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications. See 69 Fed. Reg. 56481. In accordance with this amendment, cited U.S. patents and U.S. patent application publications are not enclosed.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Date: <u>10 / 30</u>, 2006

By:

Lisa M.W. Hillman

Registration No. 43,673

McDonnell Boehnen Hulbert & Berghoff LLP

300 South Wacker Drive, 32<sup>nd</sup> Floor

Chicago, IL 60606

Telephone: 312-913-0001 Facsimile: 312-913-0002

02-742-E (400/130)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form Complete if Known 1449/PTO NOV 0 2 2006 Application No. 10/664,668 **SECOND SUPPLEMENTAL** INFORMATION DISCLOSURE Filing Date: September 18, 2003 First Named Inventor McSwiggen et al. ATEMENT BY APPLICANT Art Unit 1635 (Use as many sheets as necessary) **Examiner Name** unassigned of 2 Sheet Attorney Docket Number

1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (if known)</sup>	Publication Date  MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Α	US-5,587,471	12-1996	Cook et al.	
	В	US-5,916,763	06-1999	Wiliams et al.	
	С	US-6,710,174	03-23-2004	Bennett et al.	
	D	US-2003/0186920	10-2003	Sirois, Martin G.	
	E	ÜŚ-2003/0216335	11-2003	Lockridge et al.	
	F	US-2004/0018176	01-2004	Tolentino et al.	
	G	US-2004/0209832	10-2004	McSwiggen et al.	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
	1	Caplen, Nathan, "RNAi as a gene therapy approach, " Expert Opin. Biol. Ther: 3(4):575-586 (2003)		
	2	Hammond, et al., "Post-transcriptional Gene Silencing by Double-Stranded RNA," Nature Reviews, 2:110-119 (2001)		
	3	Mahato et al., "Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA," Expert Opin. Drug Deliv., 2(1):3-28 (2005)		
	4	Scherer et al., "Approaches for the sequence-specific knockdown of mRNA," Nature Biotechnology, 21:12, 1457-1465 (2003)		
	5	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," Nucleic Acids Research 24:573-581 (1996)		

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
	SECOND SUPP	LEMENTAL		Application No.	10/664,668
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			RE	Filing Date:	September 18, 2003
				First Named Inventor	McSwiggen et al.
				Art Unit	1635
	·			Examiner Name	unassigned
Sheet	2	of	2	Attorney Docket Number	02-742-E (400/130)

6	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," The Journal of Biological Chemistry, 278:9, 7108-7118 (2003)	
7	Zhang et al., "Targeted Gene Silencing by Small Interfering RNA-based Knock-Down Technology," Current Pharmaceutical Biotechnology, 5, 1-7 (2004)	

Examiner	Date
Signature	Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**